Search results
Results from the WOW.Com Content Network
Atomoxetine is sometimes used in the treatment of cognitive impairment and frontal lobe symptoms due to conditions like traumatic brain injury (TBI). [44] [45] It is used to treat ADHD-like symptoms such as sustained attentional problems, disinhibition, [46] lack of arousal, fatigue, and depression, including symptoms from cognitive disengagement syndrome. [44]
Stelazine (trifluoperazine) – an antipsychotic used in the treatment of psychotic disorders, anxiety, and nausea caused by chemotherapy [2] Strattera (atomoxetine) – a non-stimulant medication used to treat ADHD; Suboxone (buprenorphine/naloxone) - a partial opioid agonist used in the treatment of opioid use disorder
The dose should be increased after a minimum of 3 days up to approximately 1.2 mg/kg daily (target dose) as a single or two divided doses (in the morning and late afternoon). For children older than 6 years old, over 70 kg, acute treatment should be started with 40 mg/day orally and increased up to 80 mg/day after a minimum of 3 days.
A study published in the American Journal of Psychiatry in September 2024 alarmingly found that high dose prescription amphetamines — which are stimulants and a first-line treatment for ADHD ...
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress.. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication.
Just 100 micrograms of MM120 led to a 48% rate of remission from generalized anxiety disorder after 12 weeks, MindMed reported.
This is a list of investigational social anxiety disorder drugs, or drugs that are currently under development for clinical use in the treatment of social anxiety disorder (SAD; or social phobia) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
It's important to understand why teens use or misuse drugs, so the right resources and education can help them, Dr. Nora Volkow, director of the National Institute on Drug Abuse, wrote in an email.